Hides Leanne, Quinn Catherine, Stoyanov Stoyan, Kavanagh David, Baker Amanda
The University of Queensland, School of Psychology, St Lucia, Brisbane, Queensland, Australia, 4072.
Queensland University of Technology, School of Psychology and Counselling, Institute of Health and Biomedical Innovation, 60 Musk Avenue, Kelvin Grove, Brisbane, Queensland, Australia, 4059.
Cochrane Database Syst Rev. 2019 Nov 26;2019(11):CD009501. doi: 10.1002/14651858.CD009501.pub2.
Comorbid depression and substance use disorders are common and have poorer outcomes than either disorder alone. While effective psychological treatments for depression or substance use disorders are available, relatively few randomised controlled trials (RCTs) have examined the efficacy of these treatments in people with these comorbid disorders.
To assess the efficacy of psychological interventions delivered alone or in combination with pharmacotherapy for people diagnosed with comorbid depression and substance use disorders.
We searched the following databases up to February 2019: Cochrane Central Register of Controlled Trials, PubMed, Embase, CINAHL, Google Scholar and clinical trials registers. All systematic reviews identified, were handsearched for relevant articles.
The review includes data from RCTs of psychological treatments for people diagnosed with comorbid depression and substance use disorders, using structured clinical interviews. Studies were included if some of the sample were experiencing another mental health disorder (e.g. anxiety); however, studies which required a third disorder as part of their inclusion criteria were not included. Studies were included if psychological interventions (with or without pharmacotherapy) were compared with no treatment, delayed treatment, treatment as usual or other psychological treatments.
We used standard methodological procedures expected by Cochrane.
Seven RCTs of psychological treatments with a total of 608 participants met inclusion criteria. All studies were published in the USA and predominately consisted of Caucasian samples. All studies compared different types of psychological treatments. Two studies compared Integrated Cognitive Behavioural Therapy (ICBT) with Twelve Step Facilitation (TSF), another two studies compared Interpersonal Psychotherapy for Depression (IPT-D) with other treatment (Brief Supportive Therapy (BST) or Psychoeducation). The other three studies compared different types or combinations of psychological treatments. No studies compared psychological interventions with no treatment or treatment as usual control conditions. The studies included a diverse range of participants (e.g. veterans, prisoners, community adults and adolescents). All studies were at high risk of performance bias, other main sources were selection, outcome detection and attrition bias. Due to heterogeneity between studies only two meta-analyses were conducted. The first meta-analysis focused on two studies (296 participants) comparing ICBT to TSF. Very low-quality evidence revealed that while the TSF group had lower depression scores than the ICBT group at post-treatment (mean difference (MD) 4.05, 95% confidence interval (CI) 1.43 to 6.66; 212 participants), there was no difference between groups in depression symptoms (MD 1.53, 95% CI -1.73 to 4.79; 181 participants) at six- to 12-month follow-up. At post-treatment there was no difference between groups in proportion of days abstinent (MD -2.84, 95% CI -8.04 to 2.35; 220 participants), however, the ICBT group had a greater proportion of days abstinent than the TSF group at the six- to 12-month follow-up (MD 10.76, 95% CI 3.10 to 18.42; 189 participants). There were no differences between the groups in treatment attendance (MD -1.27, 95% CI -6.10 to 3.56; 270 participants) or treatment retention (RR 0.95, 95% CI 0.72 to 1.25; 296 participants). The second meta-analysis was conducted with two studies (64 participants) comparing IPT-D with other treatment (Brief Supportive Psychotherapy/Psychoeducation). Very low-quality evidence indicated IPT-D resulted in significantly lower depressive symptoms at post-treatment (MD -0.54, 95% CI -1.04 to -0.04; 64 participants), but this effect was not maintained at three-month follow-up (MD 3.80, 95% CI -3.83 to 11.43) in the one study reporting follow-up outcomes (38 participants; IPT-D versus Psychoeducation). Substance use was examined separately in each study, due to heterogeneity in outcomes. Both studies found very low-quality evidence of no significant differences in substance use outcomes at post-treatment (percentage of days abstinent, IPD versus Brief Supportive Psychotherapy; MD -2.70, 95% CI -28.74 to 23.34; 26 participants) or at three-month follow-up (relative risk of relapse, IPT-D versus Psychoeducation; RR 0.67, 95% CI 0.30 to 1.50; 38 participants). There was also very low-quality evidence for no significant differences between groups in treatment retention (RR 1.00, 95% CI 0.81 to 1.23; 64 participants). No adverse events were reported in any study.
AUTHORS' CONCLUSIONS: The conclusions of this review are limited due to the low number and very poor quality of included studies. No conclusions can be made about the efficacy of psychological interventions (delivered alone or in combination with pharmacotherapy) for the treatment of comorbid depression and substance use disorders, as they are yet to be compared with no treatment or treatment as usual in this population. In terms of differences between psychotherapies, although some significant effects were found, the effects were too inconsistent and small, and the evidence of too poor quality, to be of relevance to practice.
抑郁症与物质使用障碍共病的情况很常见,且其预后比单独患这两种疾病中的任何一种都要差。虽然有针对抑郁症或物质使用障碍的有效心理治疗方法,但相对较少的随机对照试验(RCT)研究过这些治疗方法对共病患者的疗效。
评估单独进行心理干预或联合药物治疗对被诊断为抑郁症与物质使用障碍共病患者的疗效。
截至2019年2月,我们检索了以下数据库:Cochrane对照试验中心注册库、PubMed、Embase、CINAHL、谷歌学术和临床试验注册库。对所有识别出的系统评价进行手工检索以查找相关文章。
本综述纳入了使用结构化临床访谈对被诊断为抑郁症与物质使用障碍共病患者进行心理治疗的RCT数据。如果部分样本患有另一种精神障碍(如焦虑症),则纳入该研究;然而,将第三种障碍作为纳入标准一部分的研究未被纳入。如果将心理干预(有或无药物治疗)与不治疗、延迟治疗、常规治疗或其他心理治疗进行比较,则纳入该研究。
我们采用了Cochrane预期的标准方法程序。
七项心理治疗的RCT共608名参与者符合纳入标准。所有研究均在美国发表,且样本主要为白种人。所有研究都比较了不同类型的心理治疗。两项研究比较了综合认知行为疗法(ICBT)与十二步促进法(TSF),另外两项研究比较了抑郁症人际心理治疗(IPT-D)与其他治疗(简短支持性治疗(BST)或心理教育)。其他三项研究比较了不同类型或心理治疗的组合。没有研究将心理干预与不治疗或常规治疗对照条件进行比较。这些研究纳入了各种各样的参与者(如退伍军人、囚犯、社区成年人和青少年)。所有研究都存在较高的实施偏倚风险,其他主要偏倚来源包括选择、结果检测和失访偏倚。由于研究之间存在异质性,仅进行了两项荟萃分析。第一项荟萃分析聚焦于两项研究(296名参与者),比较了ICBT与TSF。非常低质量的证据显示,虽然TSF组在治疗后抑郁评分低于ICBT组(平均差(MD)4.05,95%置信区间(CI)1.43至6.66;212名参与者),但在6至12个月随访时,两组抑郁症状无差异(MD 1.53,95%CI -1.73至4.79;181名参与者)。治疗后,两组在戒断天数比例上无差异(MD -2.84,95%CI -8.04至2.35;220名参与者),然而,在6至12个月随访时,ICBT组的戒断天数比例高于TSF组(MD 10.76,95%CI 3.1至18.42;189名参与者)。两组在治疗出勤率(MD -1.27,95%CI -6.10至3.56;270名参与者)或治疗保留率(RR 0.95,95%CI 0.72至1.25;296名参与者)上无差异。第二项荟萃分析纳入了两项研究(64名参与者),比较了IPT-D与其他治疗(简短支持性心理治疗/心理教育)。非常低质量的证据表明,IPT-D在治疗后导致抑郁症状显著降低(MD -0.54,95%CI -1.04至-0.04;64名参与者),但在一项报告随访结果的研究(38名参与者;IPT-D与心理教育)中,这种效果在3个月随访时未得到维持(MD 3.80,95%CI -3.83至11.43)。由于结果存在异质性,每项研究分别对物质使用情况进行了检查。两项研究均发现非常低质量的证据表明,治疗后物质使用结果无显著差异(戒断天数百分比,IPT-D与简短支持性心理治疗;MD -2.70,95%CI -28.74至23.34;26名参与者)或3个月随访时无显著差异(复发相对风险,IPT-D与心理教育;RR 0.67,95%CI 0.30至1.50;38名参与者)。在治疗保留率上,两组之间也有非常低质量的证据表明无显著差异(RR 1.00,95%CI 0.81至1.23;64名参与者)。没有任何研究报告不良事件。
由于纳入研究数量少且质量非常差,本综述的结论受到限制。对于心理干预(单独或联合药物治疗)治疗抑郁症与物质使用障碍共病的疗效无法得出结论,因为在这一人群中,尚未将其与不治疗或常规治疗进行比较。就心理治疗之间的差异而言,尽管发现了一些显著效果,但这些效果过于不一致且微小,证据质量太差,无法应用于实践。